$506.46

-6.44 (-1.26%)

Weekly Expected Move ±2.4%

$488 $501 $513 $526 $538

NYSE · Healthcare · Medical - Care Facilities · Tech Score Neutral · Power 54 · $6.6B mcap · 13M float · 1.27% daily turnover · Short 65% of daily vol

Credit Risk of going bust: lower than 89% of companies Debt: 4.7% of company value Bonds: none of note held by US funds details ▾

Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.51 (down 99.7%), Chemed Corporation would be worth roughly what it owes.
Total debt $329.1M against a stock market value of $6.62B.
Distance to default 13.27 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $145.6M (short-term plus half of long-term), stock volatility 29.5%; Altman Z'' 8.94. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Revenue Segmentation

By Product / Service

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$2.5B +4.1% ▲

5Y CAGR: +4.0%

Gross Profit

$758M -11.2% ▼

5Y CAGR: +1.6%

Operating Income

$338M -7.7% ▼

5Y CAGR: -2.8%

Net Income

$265M -12.2% ▼

5Y CAGR: -3.7%

EPS (Diluted)

$18.42 -7.4% ▼

5Y CAGR: -1.1%

EBITDA

$422M -9.0% ▼

5Y CAGR: -1.5%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$2.1B	$2.1B	$2.3B	$2.4B	$2.5B
YoY Growth	+2.9%	-0.2%	+6.1%	+7.4%	+4.1%
Cost of Revenue	$1.4B	$1.4B	$1.5B	$1.6B	$1.8B
Gross Profit	$770M	$765M	$799M	$854M	$758M
Gross Margin	36.0%	35.8%	35.3%	35.1%	30.0%
R&D Expenses	$0	$0	$0	$0	$0
SG&A Expenses	$367M	$359M	$395M	$424M	$417M
Operating Expenses	$427M	$422M	$458M	$488M	$417M
Operating Income	$343M	$343M	$341M	$366M	$338M
Operating Margin	16.0%	16.1%	15.0%	15.1%	13.4%
Interest Expense	$2M	$5M	$3M	$2M	$2M
Income Before Tax	$350M	$330M	$350M	$399M	$356M
Tax Expense	$82M	$80M	$78M	$97M	$91M
Net Income	$269M	$250M	$273M	$302M	$265M
Net Margin	12.6%	11.7%	12.0%	12.4%	10.5%
EPS (Diluted)	$16.85	$16.53	$17.93	$19.89	$18.42
EBITDA	$411M	$393M	$414M	$464M	$422M
Shares Outstanding	16M	15M	15M	15M	14M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$606M	$640M	$647M	$619M	$625M	$639M	$658M	$673M
Cost of Revenue	$396M	$406M	$431M	$434M	$444M	$433M	$459M	$469M
Gross Profit	$210M	$234M	$216M	$185M	$181M	$206M	$199M	$204M
Gross Margin	34.6%	36.6%	33.5%	29.8%	28.9%	32.2%	30.2%	30.4%
R&D Expenses	$0	$0	$0	$0	$0	$0	$0	$0
SG&A Expenses	$102M	$104M	$106M	$99M	$106M	$106M	$114M	$115M
Operating Expenses	$118M	$120M	$122M	$117M	$106M	$106M	$114M	$115M
Operating Income	$92M	$114M	$95M	$68M	$75M	$101M	$85M	$89M
Operating Margin	15.2%	17.8%	14.6%	11.0%	12.0%	15.7%	12.9%	13.2%
Interest Expense	$427K	$499K	$329K	$443K	$2M	$521K	$512K	$2M
Income Before Tax	$101M	$120M	$96M	$71M	$84M	$105M	$89M	$91M
Tax Expense	$25M	$30M	$24M	$19M	$19M	$29M	$23M	$24M
Net Income	$76M	$90M	$72M	$52M	$64M	$77M	$66M	$68M
Net Margin	12.5%	14.1%	11.1%	8.5%	10.3%	12.0%	10.1%	10.1%
EPS (Diluted)	$5.02	$6.02	$4.86	$3.57	$4.46	$5.48	$4.85	$5.13
EBITDA	$117M	$136M	$112M	$88M	$102M	$122M	$106M	$101M
Shares Outstanding	15M	15M	15M	15M	15M	14M	14M	13M

CHE NYSE